The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2SARS-CoV-2에 결합하는 수렴형 IGHV3-53/3-66 항체에 대한 CDR1 체세포 과돌연변이의 두드러진 역할Article Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome Analysis antibodies antibody antibody affinity binding binding affinity Cdr1 contributed Coronavirus-2 COVID-19 Frequency functional germline gene Humoral immunity IGHV3-53/3-66 knowledge mAb mAbs monoclonal monoclonal antibody Mutation other coronaviruses SARS-CoV-2 somatic hypermutation. somatic hypermutations Treatment [DOI] 10.1080/22221751.2022.2063074 PMC 바로가기 [Article Type] Article
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitorsArticle Published on 2022-11-012022-11-15 Journal: Nature chemical biology [Category] SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome addition angiotensin-converting enzyme 2 antibody binding component conserved coronavirus defined Diseases epitope Epitopes highlighting inhibitor inhibitors inhibitory linker monoclonal neutralize Neutralizing activity non-neutralizing antibody omicron pandemic receptor SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 evolution SARS-CoV-2 variant target the SARS-CoV-2 Treatment viral spike protein VOCs [DOI] 10.1038/s41589-022-01140-1 PMC 바로가기
Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatmentArticle Published on 2022-11-012022-11-15 Journal: The Journal of Infection [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Abstract cilgavimab monoclonal mutations neutralizing monoclonal antibodies Omicron variant Resistance mutation SARS-CoV-2 Sequencing Tixagevimab tixagevimab. Treatment [DOI] 10.1016/j.jinf.2022.07.014 PMC 바로가기
Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation ElectrophoresisArticle Published on 2022-10-292022-11-15 Journal: The journal of applied laboratory medicine [Category] 진단, [키워드] added antibody assay interference B-cell bamlanivimab Casirivimab Cell characterization COVID-19 diagnostic Electrophoresis etesevimab evaluate evaluated Imdevimab Immunofixation immunofixation electrophoresis in vitro infused Interference medication monoclonal monoclonal antibody monoclonal antibody therapy neoplasm Patient patients plasma platform producing recognizing serum Serum protein serum protein electrophoresis. serum sample serum samples Sotrovimab sustained tested therapeutic [DOI] 10.1093/jalm/jfac064 PMC 바로가기
Type D lymphomatoid papulosis with pityriasis lichenoides et varioliformis acuta-like features in a child with parvovirus infection: a controversial diagnosis in the spectrum of lymphoid proliferations: case report and literature reviewArticle Published on 2022-10-282022-11-16 Journal: Italian Journal of Pediatrics [Category] COVID19(2023년), SARS, 치료기술, [키워드] Administered Alanine antigenic Aspartate aminotransferase Bilirubin C-reactive protein Case report CD8+/CD30+ cells children clinical response clinical suspicion Critical cytokine profile Cytokines Department Diagnosis differential diagnosis discharged disease disorder Emergency erythematous feature Fever histological history Hospitalized IFN-γ IL-10 IL-6 immunoglobulin M infectious agent infiltration introduced Laboratory test lesion lesions limits literature review lymphoid lymphomatoid Lymphomatoid papulosis lymphoproliferative Lymphoproliferative cutaneous disorders marker mechanism monoclonal morphologically necrotic Parvovirus parvovirus B19 pathogenic Perspective phenotype pityriasis lichenoides et varioliformis acuta. polymerase chain reaction positive response proliferation Rash recorded regions reported representing returned SARS-CoV-2 antigen separated skin lesions steroid Support Symptom systemic corticosteroid T-cell receptor Therapies Treatment Type Type D [DOI] 10.1186/s13052-022-01371-x PMC 바로가기
Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological EfficacyArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, 치료제, [키워드] analysis antibodies antibody antiviral efficacy association bamlanivimab/etesevimab casirivimab/imdevimab clinical conducted Course COVID-19 Delta Dual therapy Efficacy France genomic glycoprotein growth high risk highlight joint management monoclonal monoclonal antibodies monoclonal antibody Mutation mutation selection. neutralization omicron overlap Paris Patient patients died patients treated Prevent Protein resistance mechanism SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 variant SARS-CoV-2-positive patients selected selective severe COVID-19 spike Spread the Spike therapy treat Treatment treatment initiation variant variants viral genome Viral load viral mutation was done [DOI] 10.1128/spectrum.02152-22 PMC 바로가기
Respiratory Virus Surveillance Among Children with Acute Respiratory Illnesses – New Vaccine Surveillance Network, United States, 2016-2021Article Published on 2022-10-072022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] accounted acute respiratory illness Adenovirus analysis antibody-based prophylactics anticipated ARI Atypical calculate Care cause caused children circulation Clinical data clinics Community COVID-19 COVID-19 vaccine current demographic characteristics described Effectiveness eligible enrolled Enrollment estimate Health highlighting hospital Hospitalized Human rhinovirus implementation incidence Infant Infants Influenza Influenza virus Measures medical condition métapneumovirus monoclonal morbidity network New nonpharmaceutical intervention pandemic parainfluenza pathogen pathogen-specific pediatric platform proportion PROTECT respiratory respiratory syncytial virus respiratory virus risk factor RSV SARS-CoV-2 Seven severe disease Surveillance United States vaccination Vaccine virus virus [DOI] 10.15585/mmwr.mm7140a1 PMC 바로가기
Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal AntibodiesArticle Published on 2022-10-042022-11-15 Journal: Transplant International [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Administered Charlson Comorbidity Index complications COVID-19 COVID-19-related symptom death Diagnosis dose early administration early treatment Epidemiology Hospitalization incidence increased risk Infection kidney Kidney transplantation mAb mAbs monoclonal monoclonal antibodies monoclonal antibody Multivariate analysis Omicron variant onset of symptoms outcome Patient primary endpoint Primary outcome recipient role SARS-CoV-2 SARS-COV-2 infection significant decrease study period the SARS-CoV-2 Transplant vaccination vaccination. [DOI] 10.3389/ti.2022.10721 PMC 바로가기
Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants중증급성호흡기증후군 코로나바이러스 2 델타 및 오미크론 변이체에 대한 단일클론항체의 임상적 효능 및 시험관내 중화능Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Casirivimab casirivimab/imdevimab clinical Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient decrease delta variant dosage Efficacy except for exhibit Hospital stay Imdevimab in vitro in vitro data in vivo Infection mAb mAbs monoclonal monoclonal antibodies monoclonal antibody neutralization Neutralization assay neutralization capacity neutralizing capacity neutralizing effect Omicron variant Patient patients treated performed provided receiving respiratory respiratory tract respiratory viral RNA SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus sotromivab Sotrovimab the SARS-CoV-2 therapeutic therapy treated variant Viral Virus neutralization virus neutralization assay. virus neutralization assays [DOI] 10.1002/jmv.27916 PMC 바로가기 [Article Type] Article